Amdinocillin

CHEMBL530 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

325.4 g/mol

LogP

2.1

Phase

4

A penicillin-type antibiotic that binds specifically to penicillin-binding protein 2 in gram-negative bacteria, disrupting cell wall synthesis in a manner complementary to other beta-lactam antibiotics. This unique binding selectivity means it is often used in combination with other penicillins or cephalosporins for synergistic antibacterial effects.

분자량

325.4000 g/mol

LogP

2.10

TPSA

98.50 Å²

리핀스키 5의 법칙

통과

치료 영역

Bladder Cancer Prostate Cancer

작용 기전

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N2[C@H]1C(=O)O

InChI

InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/b16-9+/t10-,11+,13-/m1/s1

Molecular Formula

C15H23N3O3S

HBD / HBA

1 / 5

회전 가능 결합

3

무거운 원자

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A penicillin-type antibiotic that binds specifically to penicillin-binding protein 2 in gram-negative bacteria, disrupting cell wall synthesis in a manner complementary to other beta-lactam antibiotics. This unique binding selectivity means it is often used in combination with other penicillins or cephalosporins for synergistic antibacterial effects.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Amdinocillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL530. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36273. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Amdinocillin PillFYI에서

구조

핵심 데이터

분자식: C15H23N3O3S

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.